137 related articles for article (PubMed ID: 20431043)
1. Randomized intervention studies in human polycystic kidney and liver disease.
Schrier RW
J Am Soc Nephrol; 2010 Jun; 21(6):891-3. PubMed ID: 20431043
[No Abstract] [Full Text] [Related]
2. [Autosomal dominant polycystic kidney disease].
Horie S
Nihon Jinzo Gakkai Shi; 2011; 53(1):6-9. PubMed ID: 21370570
[No Abstract] [Full Text] [Related]
3. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
Hogan MC; Masyuk TV; Page LJ; Kubly VJ; Bergstralh EJ; Li X; Kim B; King BF; Glockner J; Holmes DR; Rossetti S; Harris PC; LaRusso NF; Torres VE
J Am Soc Nephrol; 2010 Jun; 21(6):1052-61. PubMed ID: 20431041
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
Serra AL; Poster D; Kistler AD; Krauer F; Raina S; Young J; Rentsch KM; Spanaus KS; Senn O; Kristanto P; Scheffel H; Weishaupt D; Wüthrich RP
N Engl J Med; 2010 Aug; 363(9):820-9. PubMed ID: 20581391
[TBL] [Abstract][Full Text] [Related]
5. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP
J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726
[TBL] [Abstract][Full Text] [Related]
6. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
Hogan MC; Chamberlin JA; Vaughan LE; Waits AL; Banks C; Leistikow K; Oftsie T; Madsen C; Edwards M; Glockner J; Kremers WK; Harris PC; LaRusso NF; Torres VE; Masyuk TV
Clin J Am Soc Nephrol; 2020 Sep; 15(9):1267-1278. PubMed ID: 32843370
[TBL] [Abstract][Full Text] [Related]
7. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.
Caroli A; Perico N; Perna A; Antiga L; Brambilla P; Pisani A; Visciano B; Imbriaco M; Messa P; Cerutti R; Dugo M; Cancian L; Buongiorno E; De Pascalis A; Gaspari F; Carrara F; Rubis N; Prandini S; Remuzzi A; Remuzzi G; Ruggenenti P;
Lancet; 2013 Nov; 382(9903):1485-95. PubMed ID: 23972263
[TBL] [Abstract][Full Text] [Related]
8. Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy.
Wüthrich RP; Serra AL; Kistler AD
Kidney Blood Press Res; 2009; 32(5):380-7. PubMed ID: 19887826
[TBL] [Abstract][Full Text] [Related]
9. Everolimus in patients with autosomal dominant polycystic kidney disease.
Walz G; Budde K; Mannaa M; Nürnberger J; Wanner C; Sommerer C; Kunzendorf U; Banas B; Hörl WH; Obermüller N; Arns W; Pavenstädt H; Gaedeke J; Büchert M; May C; Gschaidmeier H; Kramer S; Eckardt KU
N Engl J Med; 2010 Aug; 363(9):830-40. PubMed ID: 20581392
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus reduces polycystic liver volume in ADPKD patients.
Qian Q; Du H; King BF; Kumar S; Dean PG; Cosio FG; Torres VE
J Am Soc Nephrol; 2008 Mar; 19(3):631-8. PubMed ID: 18199797
[TBL] [Abstract][Full Text] [Related]
11. Polycystic kidney disease: a 2011 update.
Steinman TI
Curr Opin Nephrol Hypertens; 2012 Mar; 21(2):189-94. PubMed ID: 22274800
[TBL] [Abstract][Full Text] [Related]
12. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
[TBL] [Abstract][Full Text] [Related]
13. Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment.
Ponticelli C; Locatelli F
Nephrol Dial Transplant; 2010 Dec; 25(12):3809-12. PubMed ID: 20798121
[No Abstract] [Full Text] [Related]
14. Sirolimus for treatment of autosomal-dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
Liu YM; Shao YQ; He Q
Transplant Proc; 2014; 46(1):66-74. PubMed ID: 24507028
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease.
Serra AL; Kistler AD; Poster D; Krauer F; Senn O; Raina S; Pavik I; Rentsch K; Regeniter A; Weishaupt D; Wüthrich RP
Nephrol Dial Transplant; 2009 Nov; 24(11):3334-42. PubMed ID: 19525519
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.
Renken C; Fischer DC; Kundt G; Gretz N; Haffner D
Nephrol Dial Transplant; 2011 Jan; 26(1):92-100. PubMed ID: 20615907
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus therapy to halt the progression of ADPKD.
Perico N; Antiga L; Caroli A; Ruggenenti P; Fasolini G; Cafaro M; Ondei P; Rubis N; Diadei O; Gherardi G; Prandini S; Panozo A; Bravo RF; Carminati S; De Leon FR; Gaspari F; Cortinovis M; Motterlini N; Ene-Iordache B; Remuzzi A; Remuzzi G
J Am Soc Nephrol; 2010 Jun; 21(6):1031-40. PubMed ID: 20466742
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.
Stallone G; Infante B; Grandaliano G; Bristogiannis C; Macarini L; Mezzopane D; Bruno F; Montemurno E; Schirinzi A; Sabbatini M; Pisani A; Tataranni T; Schena FP; Gesualdo L
Nephrol Dial Transplant; 2012 Sep; 27(9):3560-7. PubMed ID: 22785114
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic interventions for autosomal dominant polycystic kidney disease.
Edelstein CL
Nephrol News Issues; 2008 Mar; 22(3):25-6. PubMed ID: 18372677
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibitors and autosomal dominant polycystic kidney disease.
Levey AS; Stevens LA
N Engl J Med; 2011 Jan; 364(3):287; author reply 287-9. PubMed ID: 21247327
[No Abstract] [Full Text] [Related]
[Next] [New Search]
